November 6^Mon - 8^Wed, 2023
International Convention Center (ICC) JEJU

D-Days

Rznomics

November 7^Tue, 12:30-12:55(25min.), 1F Event Hall

Rznomics Inc. is developing new RNA-based gene therapeutics for malignant and diverse incurable diseases. Rznomics’ core platform technology is trans-splicing ribozyme, which can edit target RNA through simultaneous destruction and repair (and/or reprogramming) to yield the desired therapeutic RNA, thus selectively inducing therapeutic gene activity in cells expressing the target RNA. Recently, we developed a new in vitro circular RNA preparation strategy by end-to-end self-targeting and splicing (STS) reaction during in vitro transcription using Tetrahymena group I intron,. Circular RNA (circRNA) has advantages over linear mRNA, in terms of stability by nuclease-resistance and efficient ribosome recycling. We optimized group I intron components of the self-circularization RNA construct, resulting in the improved self-circularization efficiency comparable to, or potentially better than, permuted intron-exon (PIE) method. In addition, we optimized IP-RP HPLC purification method. CircRNAs with CVB3 IRES showed efficient protein expression in cells at levels comparable to circRNAs prepared by PIE. Most importantly, circRNAs generated with unmodified nucleotides by STS reaction does not harbor any extraneous fragments, in contrast to those by PIE method. Moreover, they induced negligible innate immunity in cells. Here, we introduce our novel, rapid, and more simple and efficient circRNA preparation method for diverse applications and the recent updates.